Search Result

Results for "

SDMA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Endogenous Metabolite (4) Histone Methyltransferase (8) Methionine Adenosyltransferase (MAT) (1) NF-κB (3) NO Synthase (3) Reference Standards (1)
By Research Areas:	Cancer (9) Inflammation/Immunology (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101410

*SDMA* 1 Publications Verification Symmetric dimethylarginine; NG,NG'-Dimethyl-L-arginine	Endogenous Metabolite NO Synthase NF-κB	Inflammation/Immunology
SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.

HY-101410S

SDMA-d6 Symmetric dimethylarginine-d₆; NG,NG'-Dimethyl-L-arginine-d₆	Endogenous Metabolite	Inflammation/Immunology
SDMA-d₆ is the deuterium labeled SDMA. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity .

HY-139611C

Navlimetostat hydrochloride 3 Publications Verification MRTX-1719 hydrochloride	Histone Methyltransferase	Cancer
Navlimetostat hydrochloride is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC₅₀ of less than 10 nM in PRMT5/MTA MTAP ^DEL SDMA cells .

HY-131493

PF-06939999 PRMT5-IN-3	Histone Methyltransferase Apoptosis	Cancer
PF-06939999 (PRMT5-IN-3) is a SAM-competitive, orally active PRMT5 inhibitor that inhibits the expression of SDMA protein (IC₅₀ in A427 is 1.1 nM). PF-06939999 exhibits antitumor effect .

HY-126256A

PRMT5-IN-1 hydrochloride	Histone Methyltransferase	Cancer
PRMT5 IN-1 hydrochloride (compound 9), a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC₅₀ of 11 nM for PRMT5/MEP50. PRMT5 IN-1 hydrochloride can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .

HY-101410R

SDMA (Standard) Symmetric dimethylarginine (Standard); NG,NG'-Dimethyl-L-arginine (Standard)	Reference Standards Endogenous Metabolite NO Synthase NF-κB	Inflammation/Immunology
SDMA (Standard) is the analytical standard of SDMA. This product is intended for research and analytical applications. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.

HY-101410A

SDMA (p-hydroxyazobenzene-p′-sulfonate) Symmetric dimethylarginine (p-hydroxyazobenzene-p′-sulfonate); NG,NG'-Dimethyl-L-arginine (p-hydroxyazobenzene-p′-sulfonate)	Endogenous Metabolite NO Synthase NF-κB	Inflammation/Immunology
SDMA p-hydroxyazobenzene-p′-sulfonate is the p-hydroxyazobenzene-p′-sulfonate salt form of SDMA (HY-101410). SDMA p-hydroxyazobenzene-p′-sulfonate is an endogenous inhibitor of nitric oxide synthase (NO synthase) activity. SDMA p-hydroxyazobenzene-p′-sulfonate is an activator for NF-κB, and promotes the expression of IL-6 and TNF-α. SDMA p-hydroxyazobenzene-p′-sulfonate is stable in serum and plasma, and can be used as a kidney biomarker of hepatic and renal dysfunction .

HY-172732

PRMT5-IN-50	Histone Methyltransferase	Cancer
PRMT5-IN-50 is an orally active and selective inhibitor of PRMT5. PRMT5-IN-50 has good metabolic stability and low clearance rate in human liver microsomes. PRMT5-IN-50 inhibits SDMA/HCT116-MTAPdel and SDMA/HCT116-MTAPwt with IC₅₀s value of 1.0, 536 nM for arginine symmetric methylation, 19, 1620 nM for anti-proliferation, respectively. PRMT5-IN-50 inhibits tumor growth in mice .

HY-168263

PRMT5-IN-45	Histone Methyltransferase Apoptosis	Cancer
PRMT5-IN-45 (compound 36) is a potent and selective PRMT5 inhibitor with an IC₅₀ of 3 nM. PRMT5-IN-45 potently reduces the level of symmetric dimethylarginines (sDMA) and inhibits the proliferation of MOLM-13 cell lines by inducing apoptosis and cell cycle arrest .

HY-126256

PRMT5-IN-1	Histone Methyltransferase	Cancer
PRMT5 IN-1, a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC₅₀ of 11 nM for PRMT5/MEP50. PRMT5 IN-1 can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .

HY-138684

MRTX9768	Histone Methyltransferase	Cancer
MRTX9768 is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .

HY-138684A

MRTX9768 hydrochloride	Histone Methyltransferase	Cancer
MRTX9768 hydrochloride is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .

HY-170906S

MAT2A-IN-23	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

Cat. No.	Product Name	Type

HY-101410A

SDMA (p-hydroxyazobenzene-p′-sulfonate) Symmetric dimethylarginine (p-hydroxyazobenzene-p′-sulfonate); NG,NG'-Dimethyl-L-arginine (p-hydroxyazobenzene-p′-sulfonate)	Biochemical Assay Reagents
SDMA p-hydroxyazobenzene-p′-sulfonate is the p-hydroxyazobenzene-p′-sulfonate salt form of SDMA (HY-101410). SDMA p-hydroxyazobenzene-p′-sulfonate is an endogenous inhibitor of nitric oxide synthase (NO synthase) activity. SDMA p-hydroxyazobenzene-p′-sulfonate is an activator for NF-κB, and promotes the expression of IL-6 and TNF-α. SDMA p-hydroxyazobenzene-p′-sulfonate is stable in serum and plasma, and can be used as a kidney biomarker of hepatic and renal dysfunction .

SDMA (p-hydroxyazobenzene-p′-sulfonate)

Symmetric dimethylarginine (p-hydroxyazobenzene-p′-sulfonate); NG,NG'-Dimethyl-L-arginine (p-hydroxyazobenzene-p′-sulfonate)

Biochemical Assay Reagents

SDMA p-hydroxyazobenzene-p′-sulfonate is the p-hydroxyazobenzene-p′-sulfonate salt form of SDMA (HY-101410). SDMA p-hydroxyazobenzene-p′-sulfonate is an endogenous inhibitor of nitric oxide synthase (NO synthase) activity. SDMA p-hydroxyazobenzene-p′-sulfonate is an activator for NF-κB, and promotes the expression of IL-6 and TNF-α. SDMA p-hydroxyazobenzene-p′-sulfonate is stable in serum and plasma, and can be used as a kidney biomarker of hepatic and renal dysfunction .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-101410

*SDMA* 1 Publications Verification Symmetric dimethylarginine; NG,NG'-Dimethyl-L-arginine	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease markers Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite NO Synthase NF-κB
SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.

HY-101410R

SDMA (Standard) Symmetric dimethylarginine (Standard); NG,NG'-Dimethyl-L-arginine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Ketones, Aldehydes, Acids Source classification Disease markers Endogenous metabolite	Reference Standards Endogenous Metabolite NO Synthase NF-κB
SDMA (Standard) is the analytical standard of SDMA. This product is intended for research and analytical applications. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.

Cat. No.	Product Name	Chemical Structure

HY-101410S

SDMA-d6
SDMA-d₆ is the deuterium labeled SDMA. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity .

HY-170906S

MAT2A-IN-23
MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

MAT2A-IN-23

MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

SDMA

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products